Deflazacort and bone mass

Clinical and Experimental Rheumatology

Volumn 18, Issue 5 SUPPL. 21, 2000, Pages

  Lo Cascio, V ^a  

^a Medicina Interna C   (Italy)

Author keywords

Bone densitometry; Bone histomorphometry; Bone mass; Deflazacort; Glucocorticoid osteoporosis

Indexed keywords

DEFLAZACORT; PREDNISOLONE;

BIOEQUIVALENCE; BONE ATROPHY; BONE DENSITY; BONE MASS; CALCIUM BALANCE; CLINICAL TRIAL; DENSITOMETRY; DOSE RESPONSE; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FRACTURE; HUMAN; INFLAMMATORY DISEASE; MORPHOMETRICS; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0033781203     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Trabecular architecture in women and men of similar bone mass with and without vertebral fracture. II. Three-dimensional histology
2. Relationsips between quantitative histological measurements and non invasive assessments of bone mass
3. A structural approach to renal bone disease
4. Glucocorticoid osteoporosis: A longitudinal study
5. Bone loss in response to long-term glucocorticoid therapy
6. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: Prednisone versus deflazacort
7. Corticosteroid osteoporosis
8. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis
9. The effects of sex steroids and corticosteroid hormones on bone
10. Intact parathyroid homone levels are not elevated in glucocorticoid-treated subjects
11. Corticosteroid-induced bone loss in men
12. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man
13. New developments in the pathogenesis and treatment of steroid-induced osteoporosis
14. Bone loss after glucocorticoid therapy
15. Determination of vertebral mineral density in patients receiving chronic glucocorticoid therapy
16. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteoclasts by glucocorticoids: Potential mechanisms of their deleterious effects on bone
17. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip
18. Corticosteroids and fractures: A close encounter of the third cell kind
19. Effects of a new glucocorticoid, oxacort, on some variables connected with bone metabolism in man: A comparison to prednisone
20. Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man
21. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders
22. Effects of prednisone and deflazacort on vertebral bone mass
23. The effects of small doses of deflazacort vs prednisone on the bone mineral content of lumbar spine in male patients with rheumatoid arthitis
24. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic arthritis: A relatively bone-sparing effect of deflazacort
25. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis
26. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort
27. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome
28. Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation
29. Experience with deflazacort in children and adolescents after renal transplantation
30. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: A randomized, double blind study in kidney transplant patients
31. Long-term fracture prediction by bone mineral assessed at different skeletal sites
32. Changes in bone mass during low dose corticosteroid treatment in patients with polymyalgis rheumatica: A double blind, prospective comparison between prednisolone and deflazacort
33. Effect of single oral dose of prednisone and deflazacort on human lynphocyte distribution and function. Analysis with monoclonal antibodies
34. Potency ratio - A brief synopsis
35. Long-term treatment of chronic inflammatory disorders with deflazacort
36. Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome, a pilot sudy
37. A randomized trial of deflazacort vs 6-methyl-prednisone in renal transplantation: Immunosuppressive activity and side effects
38. A long-term prospective study of equipotency between deflazacort and prednisone in the treatment of patients with polymyalgia rheumatica
39. Deflazacort: Toward selective glucocorticoid receptor modulation?
40. Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects
41. Glucocorticoid osteoperosis - Mechanisms and management